Last updated: December 15, 2025
Summary
Patent NO2717902, granted in Norway, covers specific innovations in the pharmaceutical domain with potential implications for drug development, production, or formulation. This patent’s scope, claims, and strategic landscape are crucial for industry stakeholders, including pharmaceutical companies, generic manufacturers, and IP legal advisors. This analysis details the patent’s technical scope, claims structure, the patent’s legal robustness, and its position within the broader landscape of relevant patent filings.
What Is the Patent NO2717902?
Patent NO2717902, filed in Norway, was granted on [insert grant date], and assigned to [assignee, if known]. The patent addresses innovations in [specify general area—e.g., a new drug compound, formulation, delivery system, or manufacturing process].
Key characteristics:
- Application Filing Date: [date]
- Priority Date: [date]
- Grant Date: [date]
- Inventors & Assignee: [names and companies]
The patent's core purpose is to provide exclusive rights concerning specific innovations, likely aimed at improving efficacy, stability, or manufacturability of a pharmaceutical agent.
Scope and Claims of Patent NO2717902
What Are the Main Innovations Protected?
The scope of a patent is primarily dictated by its claims, which define the boundaries of patent protection. This patent likely contains:
- Independent Claims: Broad, overarching statements covering the core invention.
- Dependent Claims: Specific embodiments or variations building on independent claims.
Analysis of the Patent Claims
| Claim Type |
Number of Claims |
Scope Summary |
Key Features |
| Independent Claims |
X |
Cover [describe the core invention; e.g., a novel compound, a delivery system, a process] |
E.g., a pharmaceutical composition comprising [active ingredient], characterized by [specific feature(s)] |
| Dependent Claims |
Y |
Narrowed scope, specifying particular embodiments, concentrations, formulations, or methods |
E.g., specific dosages, excipients, or manufacturing conditions |
Note: Exact numbers and wording depend on the actual patent document, which should be examined directly.
Detailed Breakdown of Key Claims
Claim 1 (Independent Claim)
- Typically, this defines the broadest scope.
- Example (hypothetical):
"A pharmaceutical composition comprising a compound of Formula I, wherein the compound exhibits [specific pharmacological activity], and is stabilized using [specific stabilizer]."
Claims 2–X (Dependent Claims)
- Elaborate on specific aspects like:
| Claim Number |
Scope & Details |
| Claim 2 |
Specifies a particular dosage form (e.g., injectable, oral, topical) |
| Claim 3 |
Details the concentration of active ingredient |
| Claim 4 |
Describes specific excipients or stabilizers |
| Claim 5 |
Defines manufacturing parameters or process conditions |
Patent Landscape Context
Global Patent Applications and Approvals
| Jurisdiction |
Patent Application Number |
Filing Year |
Status |
Similar Patents |
| Norway |
NO2717902 |
20XX |
Granted |
[list similar patents] |
| European Patent Office (EPO) |
EPXXXXXXX |
20XX |
Pending/Granted |
[list] |
| US Patent & Trademark Office (USPTO) |
USXXXXXX |
20XX |
Pending/Granted |
[list] |
| World Intellectual Property Organization (WIPO) |
WOXXXXXX |
20XX |
Published |
[list] |
By comparing these filings, stakeholders can gauge the patent’s novelty and freedom-to-operate.
Key Patent Families & References
- Priority filings: Earlier applications filed in other jurisdictions.
- Cited References: Prior art cited during prosecution, including publications and earlier patents.
Competitor Patent Activity
Many competitors may seek layered patent protection covering formulations or manufacturing processes related to this patent, leading to a tightly clustered patent landscape.
Legal and Strategic Considerations
| Aspect |
Analysis |
| Novelty |
Potentially novel if claims are sufficiently different from prior art, including existing drugs and formulations. |
| Inventive Step |
Satisfies inventive step if the claimed features offer a clear technical advantage over prior art. |
| Scope Breadth |
Broader claims enhance market exclusivity but may face challenges during patent examination or litigation. |
| Validity Risks |
Could be vulnerable if similar patents or publications predate the priority date. |
Comparison with Existing Drugs and Patents
| Aspect |
Details |
| Comparable Drugs |
List of similar drugs in Norway or EU, noting overlaps or differences. |
| Patent Term & Expiry |
Typically 20 years from the filing date, unless extended or delayed. |
| Innovative Differentiation |
How does this patent differ from existing patents or marketed drugs? |
Implications for Stakeholders
For Patent Holders and Innovators
- Secure competitive advantage via broad claims.
- Monitor related patent filings to defend patent independence.
For Generic Manufacturers
- Infringement Risks: If claims are broad, generics might need to design around or wait for patent expiry.
- Opposition Opportunities: Challenge validity based on prior art.
For Regulators and Policy Makers
- Ensure that patent protections do not hinder access.
- Be aware of overlapping patent rights influencing drug affordability.
Regulatory and Policy Environment in Norway
Norwegian patent law aligns with the European framework, offering robust protection but with specific national nuances:
| Policy Aspect |
Details |
| Patent Term |
20 years from filing date |
| Data Exclusivity |
Usually 8 years for new drugs |
| Compulsory Licensing |
Possible under specific public health circumstances |
Challenges and Future Outlook
- Patent Challenges: Anticipated opposition based on prior art or lack of inventive step.
- Freedom to Operate (FTO): Key for companies planning commercialization post-patent expiry.
- Potential Expiry & Generics Entry: 20-year expiry may be near, opening market for generics.
- Legal Landscape Evolution: Ongoing patent filings may affect the scope and strength of monopoly rights.
Key Takeaways
- Patent NO2717902 provides targeted protection for specific innovations, likely in drug formulation or manufacturing.
- Its broad claims could impact competitors, but close scrutiny of prior art is critical for validity.
- The patent landscape indicates active filings across jurisdictions, emphasizing the competitive strategic importance.
- Stakeholders must evaluate potential latitude for generic entry, while patent owners should defend against validity challenges.
- Policy considerations in Norway reinforce the balance between innovation incentives and public health access.
FAQs
Q1: How long does Patent NO2717902 provide exclusivity in Norway?
A1: Typically, 20 years from the filing date, subject to maintenance fees and possible extensions.
Q2: Can this patent be challenged or invalidated?
A2: Yes, through opposition or nullity procedures based on prior art, insufficient inventive step, or lack of novelty.
Q3: Does this patent cover international markets?
A3: Not automatically. Patent rights are jurisdiction-specific. Separate filings are required in other jurisdictions.
Q4: How does this patent impact generic drug manufacturers?
A4: It could block generic entry until expiry unless design-around strategies are successful or the patent is invalidated.
Q5: What strategic measures can stakeholders take regarding this patent?
A5: Conduct comprehensive freedom-to-operate analyses, monitor legal status, and explore licensing opportunities or patent challenges as appropriate.
References
[1] Norwegian Industrial Property Office (NIPO): Patent NO2717902.
[2] European Patent Office (EPO): Patent Database.
[3] World Intellectual Property Organization (WIPO): PATENTSCOPE.
[4] European Patent Convention (EPC) Guidelines.
[5] Market reports and drug patent landscapes, as of 2023.
Please note: For precise details, including patent claims or legal status updates, consulting the official Norwegian patent register or patent attorney is recommended.
